World Investment Advisors LLC Buys 3,750 Shares of Novo Nordisk A/S (NYSE:NVO)

World Investment Advisors LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 36.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,925 shares of the company’s stock after purchasing an additional 3,750 shares during the quarter. World Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,655,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Natixis Advisors LLC boosted its stake in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Zions Bancorporation N.A. lifted its position in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after buying an additional 37,346 shares during the period. LRI Investments LLC increased its stake in Novo Nordisk A/S by 103.4% in the third quarter. LRI Investments LLC now owns 12,884 shares of the company’s stock valued at $1,534,000 after acquiring an additional 6,550 shares during the period. Finally, Private Wealth Partners LLC raised its position in Novo Nordisk A/S by 155.1% in the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after purchasing an additional 20,188 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $106.95 on Friday. Novo Nordisk A/S has a 52 week low of $96.53 and a 52 week high of $148.15. The business’s fifty day moving average is $110.59 and its two-hundred day moving average is $126.22. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $479.94 billion, a P/E ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.